E-mail to a friend

If you would like to send this site to a friend, just complete the form below and click "Submit." Your friend will receive an e-mail with a direct URL link to this information, along with a notification that you requested to send it.

Your e-mail address and that of your recipient will be used for transmission only and will not be stored or used for any other purposes. Please visit www.azprivacystatement.com to review our privacy statement.

Enter the following information and click "Submit."

Your E-mail Address: (required)

Your Friend's E-mail Address: (required)

E-MAIL TO A FRIEND

PRINT THIS PAGE

Important Information About ARIMIDEX

ARIMIDEX is approved for adjuvant treatment (treatment following surgery with or without radiation) of postmenopausal women with hormone receptor-positive early breast cancer.

ARIMIDEX is approved for the initial treatment of postmenopausal women with hormone receptor-positive or hormone receptor-unknown locally advanced or metastatic breast cancer and for the treatment of postmenopausal women with advanced breast cancer that has progressed following treatment with tamoxifen. Patients with hormone receptor-negative disease and patients who did not previously respond to tamoxifen therapy rarely responded to ARIMIDEX.

Important Safety Information About ARIMIDEX

Prescription ARIMIDEX is only for postmenopausal women. ARIMIDEX should not be taken if you are pregnant because it may harm your unborn child.

In the early breast cancer clinical trial, the most common side effects seen with ARIMIDEX include hot flashes, joint symptoms, weakness, mood changes, pain, sore throat, nausea and vomiting, depression, high blood pressure, osteoporosis, swelling of arms/legs, and headache. Fractures (including fractures of the spine, hip, and wrist) occurred more frequently with ARIMIDEX than with tamoxifen (10% vs 7%).

In advanced breast cancer trials, the most common side effects seen with ARIMIDEX versus tamoxifen include hot flashes, nausea, decreased energy and weakness, pain, back pain, bone pain, and increased cough. Joint pain/stiffness has been reported in association with the use of ARIMIDEX.

ARIMIDEX should not be taken with tamoxifen or estrogen-containing therapies.

Please click here for full Prescribing Information.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.FDA.gov/medwatch or call 1-800-FDA-1088.

This site is intended for US consumers/patients. If you are a non-US consumer/patient, click here.

ARIMIDEX is a registered trademark of the AstraZeneca group of companies.

All other registered trademarks are the property of their respective owners.

©2008 AstraZeneca Pharmaceuticals LP. All rights reserved. 269225 10/08

US Corporate Site